S095024
PreclinicalSmall molecule
S095024 is one of 25 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Non-Small Cell Lung Cancer (NSCLC)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Trodelvy
GileadPhase 3
DATROWAY
Daiichi SankyoPhase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
Xospata
AstellasPhase 1
Rina-S
GenmabPhase 2
Rasonque
Revolution MedicinesPhase 1
Pemetrexed/carboplatin
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S095024. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SServier Bio-Innovation LLC